Abstract
Pancreatic cancer is one of the most lethal cancers and leading cause of cancer related death worldwide. Due to its nonspecific early symptoms, pancreatic cancer is difficult to diagnose before extensive local invasion and distant metastasis. The 5-year survival rate of patients diagnosed with pancreatic cancer is less than 5%. Their median survival time is less than 12 months. The molecular mechanisms of pancreatic tumor genesis are poorly understood. Mesothelin is a glycosylphosphatidylinositol (GPI) anchored cell surface protein, which has been found overexpressed in human pancreatic cancer. The function of mesothelin in tumor progression remains unclear. This review aims to outline the roles of mesothelin in pancreatic cancer cell proliferation, apoptosis and invasion, as well as its potential role in mesothelintargeted cancer therapy. Therefore, mesothelin is malignant factor for pancreatic cancer and could be exploited as an antigenic target of therapeutic cancer vaccine.
Keywords: Function, mesothelin, pancreatic cancer.
Current Signal Transduction Therapy
Title:Clinical Significance of Mesothelin in Pancreatic Cancer
Volume: 11 Issue: 1
Author(s): Lei Zhang, Xiaoling Ni and Dayong Jin
Affiliation:
Keywords: Function, mesothelin, pancreatic cancer.
Abstract: Pancreatic cancer is one of the most lethal cancers and leading cause of cancer related death worldwide. Due to its nonspecific early symptoms, pancreatic cancer is difficult to diagnose before extensive local invasion and distant metastasis. The 5-year survival rate of patients diagnosed with pancreatic cancer is less than 5%. Their median survival time is less than 12 months. The molecular mechanisms of pancreatic tumor genesis are poorly understood. Mesothelin is a glycosylphosphatidylinositol (GPI) anchored cell surface protein, which has been found overexpressed in human pancreatic cancer. The function of mesothelin in tumor progression remains unclear. This review aims to outline the roles of mesothelin in pancreatic cancer cell proliferation, apoptosis and invasion, as well as its potential role in mesothelintargeted cancer therapy. Therefore, mesothelin is malignant factor for pancreatic cancer and could be exploited as an antigenic target of therapeutic cancer vaccine.
Export Options
About this article
Cite this article as:
Zhang Lei, Ni Xiaoling and Jin Dayong, Clinical Significance of Mesothelin in Pancreatic Cancer, Current Signal Transduction Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574362411666160210232918
DOI https://dx.doi.org/10.2174/1574362411666160210232918 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Antisense Strategies
Current Molecular Medicine IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets